Citius Oncology, Inc.
CTOR Nasdaq
SEC CIK 1851484
Follow Citius Oncology
Weekly email: filings, results
Revenue, last quarter
$1.5M
Net income
−$8.9M
−66.2% vs same quarter last year
EPS, diluted
−$0.08
+0% vs same quarter last year
Operating cash flow
−$2.7M
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$24.8M |
| FY24 | −$21.1M |
| FY23 | −$12.7M |
| FY22 | - |
| FY21 | - |